Menu
Search
|

Menu

Close
X

CRISPR Therapeutics AG CRSP.OQ (NASDAQ Stock Exchange Global Market)

40.01 USD
-0.61 (-1.50%)
As of Feb 17
chart
Previous Close 40.62
Open 40.88
Volume 192,042
3m Avg Volume 165,942
Today’s High 42.08
Today’s Low 39.50
52 Week High 44.96
52 Week Low 13.50
Shares Outstanding (mil) 40.59
Market Capitalization (mil) 783.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
9
FY16
5
FY15
0
EPS (USD)
FY17
-1.716
FY16
0.382
FY15
-0.642
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
76.97
5.77
Price to Book (MRQ)
vs sector
3.91
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-16.50
14.43
Return on Equity (TTM)
vs sector
-56.05
16.13

EXECUTIVE LEADERSHIP

Rodger Novak
Chairman of the Board of Directors, President, Founder, Since 2017
Salary: $356,242.00
Bonus: $118,424.00
Samarth Kulkarni
Chief Executive Officer, Since 2017
Salary: $145,833.00
Bonus: $43,750.00
Kala Subramanian
Senior Vice President - Strategic Development and Operations, Since 2016
Salary: --
Bonus: --
Megan Wherry Menner
Senior Vice President of Human Resources, Since
Salary: --
Bonus: --
Sven Lundberg
Chief Scientific Officer, Since 2015
Salary: $302,605.00
Bonus: $90,928.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Aeschenvorstadt 36
BASEL     4051

Phone:

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

SPONSORED STORIES